Indian Health Minister Asks Novartis to Stand Down On Gleevec Patent Fight
This article was originally published in The Pink Sheet Daily
Executive Summary
Indian regulators threaten compulsory licensing of the oncologic, but Novartis says it has no plans to end its bid for patent protection.
You may also be interested in...
Greenwood: Future BIO Global Efforts Include International Relations
BIO joins forces with other national biotech associations to lobby the World Health Organization on intellectual property, innovation and public health.
Greenwood: Future BIO Global Efforts Include International Relations
BIO joins forces with other national biotech associations to lobby the World Health Organization on intellectual property, innovation and public health.
India Highlights "Public Interest" To Reign In Prices For Non-Scheduled Drugs
India's National Pharmaceutical Pricing Authority has imposed a 15-day deadline on 11 drug manufacturers to rein in costs of certain drugs, citing the "public interest" of lower prices for consumers